ArticleRespiratory research2026
Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundAnti-synthetase syndrome (ASS) is an autoimmune disease characterized by serum anti-aminoacyl-tRNA synthetase (ARS) antibodies and frequently associated with recurrent and refractory interstitial lung disease (ASS-ILD). Its pathogenesis remains poorly understood.
methodPaired peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage fluid (BALF) cells from 4 patients with new-onset ASS-ILD were analyzed by single-cell RNA sequencing (scRNA-seq), whereas paired plasma and BALF samples from 11 new-onset ASS-ILD patients underwent Pro-DIA proteomics. Ten patients with idiopathic pulmonary fibrosis (IPF) and 10 healthy donors served as disease and healthy controls (HC) for the proteomics. In vitro experiments were performed to support the multi-omics findings.
resultIntegrated scRNA-seq (117,960 PBMCs and 91,230 BALF cells) and Pro-DIA proteomics (4,629 plasma and 3,919 BALF proteins) analyses were performed. In ASS-ILD BALF, monocyte-macrophages showed significantly higher cytokine and inflammatory gene module scores compared with IPF and HCs (all P < 2e-16). The proportion of alveolus pro-inflammatory monocyte-macrophages was markedly increased (52.7% vs. 6.2% in IPF and 3.6% in HC). These subsets exhibited upregulated tRNA aminoacylation pathway and elevated multiple ARS gene expressions (adj.P < 1e-5). BALF proteomics also revealed increased ARS-related proteins and inflammatory mediators in ASS-ILD (adj.P < 0.05). In vitro, human histidyl ARS-containing immune complexes (IC) induced higher expression of MHC-I/II, CD80/CD86, pro-inflammatory cytokines, and ARS genes in primary human macrophages compared with control IC.
conclusionOur findings provide novel insights into ASS-ILD pathogenesis and suggest the underlying pathogenicity of ARS containing IC. These results underscore the role of monocyte-macrophage activation in ASS-ILD related immunopathogenesis and pave the way for targeted therapies directed at IC formation and aberrant monocyte-macrophage dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.